Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens which are generally overlooked during immune surveillance these neoantigens happen to be proven to own substantial therapeutic potential

London

Roots Analysis has announced adding “Neoantigen Targeted Therapies, 2019-2030” are accountable to its listing of choices.

Using neoantigens in therapy has shown the opportunity to elicit a powerful T cell mediated immune response. Several therapy candidates are now being investigated both as monotherapies and in conjunction with various immune checkpoint inhibitors, for example atezolizumab, durvalumab, ipilimumab, and nivolumab. Of those, certain pipeline candidates have previously joined mid to late-stage (phase II and above) trials and therefore are expected to go into the market within the next 5-ten years.

To buy this 320  page report, featuring 110  figures and 140  tables, check out here

Key Market Insights

Over 150  candidate therapies within the development pipeline

Nearly 13% from the pipeline therapies are now being developed to treat GI cancers, adopted by cancer of the lung (11%). Types of molecules being produced for these indications include (from a to z, no specific selection criteria) MicOryx, NCI-4650, and Tedopi®.

1,100  patents filed / granted in 2018

Actually, greater than 6,000 patents were filed / granted associated with neoantigen targeted therapies, since 1978. According to existing ip, the R&D activity was observed to become concentrated in america. Other key regions with significant intellectual capital include (in decreasing order of quantity of patents filed / granted) Australia, Europe, China, and Canada.

Near to USD 7.5 billion invested by public and private investors, since 2014

Around USD 3,200 million was elevated through investment capital financing, representing around 43% from the total capital elevated by industry players within the with time period (till April 2019). Further, within the last 5 years, there has been 10 IPOs accounting in excess of 800 million in financing of neoantigen related initiatives.

Information mill collaborating positively for that growth of numerous studies

Most of the abovementioned contracts were observed to become centered on performing Phase I / Phase II studies of neoantigen targeted therapies to treat different cancer indications. Contracts signed for research purposes (19%) were also observed to become well-liked by industry stakeholders, during 2014-2019 (till April).

Greater than 350 publications happen to be printed since 2014

It’s important to note that between your period 2014-2019, over 150 research articles were printed associated with neoantigen targeted therapies. Further, greater than 190 review articles happen to be printed associated with this approaching field.

Therapies using personalized neoantigens are expected to increase in a CAGR well over 60% between 2024 and 2030

This growth is predicted to become mainly driven through the reduced chance of negative effects and improved effectiveness of personalized therapies. The United States (mainly the united states) and Europe are anticipated to capture most share by 2030, with regards to the sales-based revenues.

Pr Release: Current Format

To request an example copy / sales brochure of the report, check out here

Key Questions Clarified

•           What would be the prevalent trends associated with R&D activity centered on neoantigen based therapies?

•           What would be the clinical conditions that neoantigen targeted therapies are now being developed?

•           What would be the key challenges faced by neoantigen-based therapy developed?

•           Who would be the leading industry and non-industry players?

•           What would be the important aspects that will probably influence the evolution from the neoantigen targeted therapies market?

•           What would be the causes of partnership activity among stakeholders within this industry?

•           Who would be the key investors in neoantigen targeted therapies?

•           What is share of neoantigen targeted therapies within the immunotherapy market?

•           How may be the current and future market chance apt to be distributed across key areas and geographies?

The USD 3 billion (by 2030) financial chance inside the neoantigens market continues to be examined over the following segments:

•           Type of target disease indication

•           Bone cancer

•           Colorectal cancer

•           Gynecological cancer

•           Non-small cell cancer of the lung

•           Renal cell carcinoma

•           Other cancers

•           Type of neoantigens

•           Personalized neoantigens

•           Off-the-shelf neoantigens

•           Type of immunotherapy

•           Dendritic cell vaccines

•           DNA / RNA-based vaccines

•           Protein / peptide-based vaccines

•           TIL-based therapies

•           Route of administration

•           Intradermal

•           Intravenous

•           Subcutaneous

•           Other routes

•           Key geographical regions

•           North America

•           Europe

•           Rest around the globe

The report features inputs from eminent industry stakeholders, based on whom neoantigen targeted therapies are anticipated is the newest part of cancer immunotherapy. Much like Vehicle-T cell therapies, these therapies have, to date, shown significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held using the following experts:

•           Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)

•           Ella Sorani (V . P . Development and research, BioLineRx)

•           Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)

Pr Release: Current Format

The study covers detailed profiles, featuring an introduction to the organization, its financial information (if available), along with a description of their product(s), highlighting kind of therapy, current development status, and key preclinical / medical trial results. Each profile includes a summary of recent developments, as well as an informed opinion around the likely strategies which may be adopted by these players to fuel development in the predicted future.

•           Bavarian Nordic

•           Genocea Biosciences

•           Gradalis

•           Immunicum

•           Immunovative Therapies

•           Iovance Biotherapeutics

•           Medigene

•           Neon Therapeutics

•           Precision Biologics

•           Vaxon Biotech